KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short term Debt (2016 - 2024)

Biomarin Pharmaceutical (BMRN) has disclosed Short term Debt for 12 consecutive years, with $494.8 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Short term Debt changed N/A year-over-year to $494.8 million, compared with a TTM value of $494.8 million through Jun 2024, changed N/A, and an annual FY2023 reading of $493.9 million, changed N/A over the prior year.
  • Short term Debt was $494.8 million for Q2 2024 at Biomarin Pharmaceutical, roughly flat from $494.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $494.8 million in Q2 2024 and bottomed at $28.3 million in Q3 2022.
  • Average Short term Debt over 5 years is $236.4 million, with a median of $64.0 million recorded in 2022.
  • The sharpest move saw Short term Debt surged 3642.9% in 2020, then crashed 87.13% in 2021.
  • Year by year, Short term Debt stood at $374.3 million in 2020, then tumbled by 87.11% to $48.2 million in 2021, then crashed by 41.32% to $28.3 million in 2022, then surged by 1644.96% to $493.9 million in 2023, then grew by 0.19% to $494.8 million in 2024.
  • Business Quant data shows Short term Debt for BMRN at $494.8 million in Q2 2024, $494.4 million in Q1 2024, and $493.9 million in Q4 2023.